NOBO Medicine

The core of the company's strategy is the development of precision medicines specifically for hemato-oncology and chronic inflammatory diseases intended for global markets. It operates within the pharmaceutical and healthcare discovery tools sectors. The business model is centered on a patient-oriented translational approach, utilizing novel biomarkers to develop targeted therapies. A key component of this model is the company's proprietary clinical database, NOBO-VERSE, which is leveraged to identify patient populations most likely to benefit from its developmental therapies. This data-driven process aims to improve the efficiency and success rates of its drug development programs.

NOBO Medicine's pipeline includes several projects at various stages of development. Notable projects include Poseltinib, which is being investigated for relapsed or refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) and Primary Central Nervous System Lymphoma (R/R PCNSL), and Emricasan for cardiovascular disease (CVD) and age-related macular degeneration (AMD). The company is also developing a selective Caspase inhibitor for inflammatory conditions and a PPM1D inhibitor for oncology. This focus on biomarker-driven drug development positions the company to create therapies for specific patient subgroups. The company's revenue model is based on the successful development and subsequent commercialization or out-licensing of these therapeutic assets. Since its inception, NOBO Medicine has attracted investment from several firms, including Curocell, Dongkuk Holdings Company, and the Industrial Bank of Korea, and received non-equity assistance from the TIPS Program in 2018.